文献园地
更多
TheranosticsDevelopment of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment
International ImmunopharmacologySiglec-E deletion alters AT macrophages phenotypes, induces an inflammatory response, and adipogenesis during diet-induced obesity
Journal of Orthopaedic ResearchDepth-Wise Changes in Tibial and Femoral Human Knee Joint Cartilage at Different Severities of Osteoarthritis
品牌库
更多tranScrip Ltd
Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive pool of Senior Partners and Partners.
Abbott B.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.
Formatech, Inc. Company dissolved
At Formatech, we help make new drugs happen… at the speed of science! Formatech, founded in 1993, provides contract services that deliver unique solutions to our clients' product development and manufacturing challenges. Our service offerings include: preformulation and formulation development of all common dosage forms, lyophilization development, cell culture/fermentation process development, purification/downstream process development and aseptic fill and finish of liquid and lyophilized dosage units. We have had excellent results developing biotherapeutic products. Our accomplishments include developing many Ab formulations at concentrations in excess of 200 mg/mL and an orally bioavailable peptide formulation. Our aseptic manufacturing facility produces liquid and lyophilized dosage units for clinical supplies or small-scale commercial products. Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and ICH conforming stability programs. Our team is accomplished at completing new projects successfully even when confronted with very aggressive timelines. Our regulatory history includes FDA inspections and three inspections by the MHRA (letters and certificate of GMP compliance received).
GUS Schweiz AG
We optimize your business processes GUS ERP GmbH, GUS Nordic ApS and GUS Schweiz AG provide GUS-OS Suite, a web-based ERP business solution that includes all industry functionalities and fulfills regulatory requirements. The companies are members of the GSG GENII Software Group (www.gsg-genii.com), which offers leading, industry-specific software solutions and services, explicitly for medium-sized companies and public administrations. With its industry knowledge and personal customer relationships, the group of companies is a trustworthy partner and expert advisor to its customers. It accompanies its customers through digitization and ensures that they are equipped for the future in a volatile environment. GENII, headquartered in Munich, Germany, has generated sales of approximately 340 million euros with around 2,400 employees. GENII is backed by Bregal Unternehmerkapital and Elvaston.
GUS ERP GmbH
As a long-standing partner of the process industry, the GUS Group combines business competence with industry expertise and offers with GUS-OS ERP one of the most comprehensive software offerings for companies in the pharmaceutical, biotechnology, cosmetics, food and beverage, chemical and logistics industries. The GUS Group provides comprehensive consulting services, carries out projects and sets up IT infrastructures. Our own development team ensures continuous software innovations and the alignment of the solution with the norms and standards in our target industries. Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here .
Dr. August Wolff GmbH & Co. KG
Dr. August Wolff GmbH & Co. KG Arzneimittel is a family owned research oriented company still located in Bielefeld, Germany. Dr. August Wolff GmbH & Co. KG is selling medicinal products, medical devices and cosmetic products like Linola and Vagisan in several European countries. Since its inception in 1905 Dr. August Wolff has maintained strong focus in collaborations with universities to foster research and development in their search for novel products.
生知快讯
最新资讯
更多
RNA结合蛋白选刊地图，5档讲清
做RNA结合蛋白的宝子，最常卡的一步不是CLIP数据跑不通，是选刊对号入座。这几年RBP从剪接调控火到相分离凝聚体，故事攒了一堆往哪投？投稿地图帮你分好档：里程碑级冲NRMCA（118.0）转录后调控综述天花板，机制大文冲Nature/Cell；专业池里Cell Research（31.1）国产旗舰接RNA机制大文，Molecular Cell（16.0）管RBP与mRNA
衰老分泌表型选刊地图，5档讲清
做衰老分泌表型的宝子，最常卡的一步不是Western跑不干净，是选刊对号入座。这两年SASP从衰老细胞因子火到inflammaging，故事攒了一堆往哪投？投稿地图帮你分好档：里程碑级冲NRMCA（118.0）衰老综述天花板，senolytics临床证据首选Nature Medicine（52.5），分泌机制大文冲Nature/Cell；专业池里Autophagy（18.6）接自噬-S
创新药每日资讯 · 2026-11-07
第 67 期创新药日报，7 条动态 3 分钟看完：报产、获批临床、FDA 优先审评、医保谈判都有新进展。① 先声药业与凌科药业合作的口服第二代 JAK1 抑制剂泽普昔替尼，类风湿关节炎适应症报产获受理，430 例 III 期数据扎实，这是它继特应性皮炎后的第二个注册适应症② 艾力斯首款自研 ADC AST1001（EGFR/c-MET 双抗 + 自研 T